| Literature DB >> 35565271 |
Nadeem O Kaakoush1, Ellen M Olzomer2, Melidya Kosasih3, Amy R Martin3,4, Farokh Fargah5, Neil Lambie6, Daniella Susic3, Kyle L Hoehn2, Rhonda Farrell7,8, Frances L Byrne2.
Abstract
Obesity is a risk factor for endometrial cancer. The aim of this study was to determine whether actively replicating microbiota in the endometrium differ between obese vs. lean and cancer vs. benign states. We performed 16S rRNA amplicon sequencing on endometrial tissues from lean and obese women with and without endometrial cancer, and lean and obese mice. Results displayed human endometrial microbiota clustered into three community types (R = 0.363, p = 0.001). Lactobacillus was dominant in community type 1 (C1) while community type 2 (C2) had high levels of Proteobacteria and more cancer samples when compared to C1 (p = 0.007) and C3 (p = 0.0002). A significant increase in the prevalence of the C2 community type was observed across body mass index and cancer (χ2 = 14.24, p = 0.0002). The relative abundance of Lactobacillus was lower in cancer samples (p = 0.0043), and an OTU with 100% similarity to Lactobacillus iners was enriched in control samples (p = 0.0029). Mouse endometrial microbiota also clustered into three community types (R = 0.419, p = 0.001) which were not influenced by obesity. In conclusion, obesity and cancer are associated with community type prevalence in the human endometrium, and Lactobacillus abundance is associated with normal uterine histologies in humans and mice.Entities:
Keywords: lactobacillus; microbiota; obesity; uterine cancer
Year: 2022 PMID: 35565271 PMCID: PMC9100094 DOI: 10.3390/cancers14092141
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Baseline characteristics and metabolic parameters of patients.
| Characteristics: | Lean Cancer | Obese Cancer | Lean Control | Obese Control | |
|---|---|---|---|---|---|
| Age (years) | 69.0 a | 68.0 | 60.5 a | 59.5 | 0.003 |
| BMI (kg/m2) | 23.74 b | 38.20 b | 23.65 b | 31.95 b | <0.0001 |
| Stage | |||||
| I A | 10 (58.8%) | 15 (65.2%) | N/A | N/A | |
| I B | 4 (23.5%) | 3 (13%) | |||
| II A | 0 (0.0%) | 1 (4.3%) | |||
| III A | 0 (0.0%) | 1 (4.3%) | |||
| III C | 1 (5.9%) | 2 (8.7%) | |||
| IV A | 1 (5.9%) | 0 (0.0%) | |||
| IV B | 1 (5.9%) | 1 (4.3%) | |||
| Grade | N/A | N/A | |||
| 1 | 13 (76.5%) | 14 (60.9%) | |||
| 2 | 3 (17.6%) | 8 (34.8%) | |||
| 3 | 1 (5.9%) | 1 (4.3%) | |||
| Parity | |||||
| 0 | 5 (29.4%) | 6 (26.1%) | 6 (33.3%) | 3 (25.0%) | |
| 1 or 2 | 9 (52.9%) | 6 (26.1%) | 8 (44.4%) | 6 (50.0%) | |
| 3 or more | 3 (17.6%) | 11 (47.8%) | 4 (22.2%) | 3 (25.0%) | |
| Gravidity | |||||
| 0 | 4 (23.5%) | 7 (30.4%) | 4 (22.2%) | 2 (16.7%) | |
| 1 or 2 | 8 (47.1%) | 4 (17.4%) | 11 (61.1%) | 6 (50.0%) | |
| 3 or 4 | 2 (11.8%) | 10 (43.5%) | 3 (16.7%) | 3 (25.0%) | |
| 5 or more | 3 (17.6%) | 2 (8.7%) | 0 (0.0%) | 1 (8.3%) | |
| Age at Menarche (years) | 13.5 ( | 13.0 | 13.0 ( | 13.0 | 0.567 |
| Age at Menopause (years) | 51.0 | 52.0 | 52.0 ( | 50.5 | 0.681 |
| Any systemic HRT history | ( | ||||
| 8 (53.3%) | 4 (17.4%) | 7 (38.9%) | 3 (25.0%) | ||
| Years on systemic HRT | 0.50 ( | 0.00 | 0.00 | 0.00 | 0.055 |
| No OCP History | ( | ( | ( | ||
| 6 (42.9%) | 9 (40.9%) | 7 (43.8%) | 6 (50.0%) | ||
| Years on OCP | 1.25 ( | 2.00 ( | 4.50 ( | 0.50 | 0.839 |
| Comorbidities | |||||
| Type 2 Diabetes | 0 (0.0%) | 5 (21.7%) | 0 (0.0%) | 4 (33.3%) | |
| Hyperlipidemia | 5 (29.4%) | 6 (26.1%) | 2 (11.1%) | 8 (66.7%) | |
| Hypertension | 6 (35.3%) | 18 (78.3%) | 1 (5.6%) | 6 (50.0%) | |
| Hypothyroidism | 4 (23.5%) | 3 (13.0%) | 4 (22.2%) | 2 (16.7%) | |
| Regular Medications | 12 (70.6%) | 19 (82.6%) | 11 (61.1%) | 9 (75.0%) | |
| Tobacco Use | ( | ( | |||
| Never | 10 (58.8%) | 11 (52.4%) | 16 (88.9%) | 8 (80.0%) | |
| Current | 2 (11.8%) | 2 (9.5%) | 0 (0.0%) | 1 (10.0%) | |
| Previous | 5 (29.4%) | 8 (38.1%) | 2 (11.1%) | 1 (10.0%) | |
| Pack Years | 0.00 | 0.00 ( | 0.00 | 0.00 ( | 0.171 |
| Glucose (mmol/L) | 4.70 c | 5.20 ( | 5.10 | 5.60 c | 0.013 |
| Insulin (μU/mL) | 4.30 d ( | 9.50 de ( | 4.80 e ( | 7.70 ( | 0.002 |
| HbA1c IFCC (mmol/mol) | 37.0 ( | 39.0 f | 34.5 fg | 40.0 g | 0.003 |
| HbA1c NGSP (%) | 5.55 ( | 5.80 h | 5.35 h | 5.80 | 0.005 |
| HDL (mmol/L) | 1.90 ( | 1.30 ( | 1.65 | 1.30 | 0.043 |
| LDL (mmol/L) | 2.80 ( | 2.85 ( | 2.45 | 1.90 | 0.233 |
| Triglycerides (mmol/L) | 1.45 ( | 1.35 ( | 1.30 ( | 1.60 ( | 0.554 |
| CRP (mg/L) | 1 i ( | 4 ij ( | 1.5 j | 3 | 0.003 |
| Estradiol (pmol/L) | 19.0 k ( | 39.5 kl ( | 16.0 l ( | 31.0 g ( | 0.005 |
a Pairwise comparison revealed a significant difference (p = 0.004#). b Pairwise comparisons revealed a significant difference between lean control group and obese control group (p = 0.002#), lean control group and obese cancer group (p = 0.000#), lean cancer group and obese control group (p = 0.002#), and lean cancer group and obese cancer group (p = 0.000#). c–l Pairwise comparisons revealed a significant difference (p < 0.05#) and m p values were calculated using the Kruskal-Wallis H Test, and # p values have been adjusted by the Bonferroni correction for multiple comparison tests. HRT (hormone replacement therapy), OCP (oral contraceptive pill), HDL (high-density lipoprotein), LDL (low-density lipoprotein), HbA1c (hemoglobin A1c) International Federation of Clinical Chemistry (IFCC), HbA1c National Glycohemoglobin Standardization Program (NGSP), C-reactive protein (CRP).
Figure 1Endometrial microbiota of patients with endometrial cancer and controls. (A): Principal coordinate (PCO) analysis of bacterial beta diversity across community types (C1-3). The ordinations were generated from Bray-Curtis resemblance matrices on square-root transformed bacterial relative abundances. Analysis of similarities (ANOSIM) was employed to test for significant differences in beta diversity. (B): Shannon’s diversity across community types. Significance was analyzed by Kruskal-Wallis with Dunn’s multiple comparisons test. *** p < 0.001. (C): Genera found to be significantly differentially abundant across community types. Taxa were identified using Linear discriminant analysis Effect Size (LEfSe). Genera with a Linear discriminant analysis (LDA) score > 4 are displayed. (D): Principal coordinate analysis of bacterial beta diversity between patients (Y, tumor sample) and controls (N). (E): Prevalence (%) of patients with endometrial cancer across community types. (F): Prevalence (%) of community types in patients and controls stratified according to body mass index (BMI). (G): Relative abundance (%) of Lactobacillus in patients and controls stratified according to BMI. Significance was tested using two-way ANOVA, * p < 0.01.
Figure 2Endometrial microbiota in tumor samples and healthy adjacent tissue. (A): Principal coordinate (PCO) analysis of bacterial beta diversity across sample types (control, green; healthy adjacent tissue, yellow; tumor tissue, red). The ordinations were generated from Bray-Curtis resemblance matrices on square-root transformed bacterial relative abundances. All paired tumor-adjacent samples except one (indicated by connecting line) classified as the same community type. (B): Comparisons of dispersions in microbiota composition within patients (tumor-adjacent) against inter-patient (adjacent and tumor). Distances were calculated using the distance-based test for homogeneity of multivariate dispersions (PERMDISP). Significance was tested by ANOVA using Tukey’s multiple comparisons test. **** p< 0.0001. (C): Genera that were significantly differentially abundant between tumor samples and adjacent normal tissue. Taxa were identified using Linear discriminant analysis Effect Size (LEfSe). Genera that had a Linear discriminant analysis (LDA) score > 4 are displayed. No taxa were identified when correction for community type was applied.
Figure 3Long-term Western diet-induced model of obesity in female mice. (A): Schematic overview of mouse study, where female mice lacking one copy of liver kinase B1 (LKB1) in the endometrium (Sprr2f-Cre: LKB1/+) or wild-type littermates (LKB1/+) were weaned at 3 weeks of age, fed chow diet until 6 weeks of age, and then continued either on chow or Western diet (WD) at 6 weeks of age. Fat mass was measured by EchoMRI and glucose tolerance tests (GTTs) were performed at 16 weeks of age. Blood samples were collected following a 17-h fast at 26 weeks of age. Mice were euthanized at ~73 weeks of age (~510 days old). Mice uteri were cut in half for histological and microbiota analysis. (B): Glucose tolerance test (GTT), whereby mice were injected with 2 g/kg glucose (intraperitoneal, i.p.) and their blood glucose levels (millimolar, mM) were measured over time. (C): Area under the curve values from the GTT for each of the 4 groups. (D): Blood glucose levels (mM) were measured in mice following a 17 h fast. (E): Percentage (%) fat mass of mice was measured using echo magnetic resonance imaging (MRI). (F): Final mouse body weights at study completion. (G): Liver weights of mice at study completion. (H): Gonadal fat weights (both pads) of mice at study completion. (I): Subcutaneous fat weights (both pads) of mice at study completion. (J): Brown fat weights of mice at study completion. Mouse numbers for each group are displayed next to the symbols, with n = 4 for LKB1/+ on chow and Western diets, n = 24 for Sprr2f-Cre: LKB1/+ mice on chow diet, and n = 29 for Sprr2f-Cre: LKB1/+ mice on Western diet (WD). Mouse data was analyzed by 2-way ANOVA with Tukey’s test for multiple comparisons (alpha = 0.05). Data bars indicate the mean and error bars indicate standard deviation. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Mouse uterine pathology.
| Pathology Results, | ||||||
|---|---|---|---|---|---|---|
| Genotype | Diet | Mice ( | Normal | Hyperplasia | Atypical | Cancer |
|
| Chow | 4 | 1 (25%) | 2 (50%) | 1 (25%) | |
|
| Western | 4 | 1 (25%) | 3 (75%) | ||
|
| Chow | 24 | 3 (12.5%) | 6 (25%) | 14 (58.3%) | 1 (4.2%) |
|
| Western | 29 | 8 (27.6%) | 7 (24.1%) | 13 (44.8%) | 1 (3.5%) |
Statistical analyses display that for all genotypes combined, there is no significant difference in Chow vs. Western/Normal vs. Disease contingency (p = 0.52 Fisher’s Exact) or Chow vs. Western/Normal vs. Hyperplasia vs. Atypical Hyperplasia (no cancer) Chi-square = 0.95, p = 0.62. Lkb1 (liver kinase B1), Cre (cre recombinase), Sprr2f (small proline-rich protein 2F), Lkb1/+ (mice are wild-type for LKB1 in the endometrium), Sprr2f-Cre; Lkb1/+ (mice are heterozygous for LKB1 in the endometrium).
Figure 4Endometrial microbiota of mice on chow or a western diet. (A): Principal coordinate (PCO) analysis of bacterial beta diversity across community types (C1-3). The ordinations were generated from Bray-Curtis resemblance matrices on square-root transformed bacterial relative abundances. Analysis of similarities (ANOSIM) was employed to test for significant differences in beta diversity. (B): Shannon’s diversity across community types. Significance was tested using Kruskal-Wallis with a Dunn multiple comparisons test. ** p < 0.01, **** p < 0.0001. (C): Genera found to be significantly differentially abundant across the community types. Taxa were identified using Linear discriminant analysis Effect Size (LEfSe) and only genera that had a linear discriminant analysis (LDA) score > 4 are displayed. (D): Principal coordinate analysis of bacterial beta diversity across pathological outcomes. Norm: normal, Hyp: hyperplasia, At Hyp: atypical hyperplasia, adeno: adenocarcinoma. (E): Results of pairwise ANOSIM tests. (F): Prevalence of pathological outcomes across community types.